Funding Alert

Lamark Biotech Raises ₹6.5 Cr in Pre-Series A Round to Advance Thermostable Insulin Innovation

• ByStartupStory     |    July 3, 2025

Ahmedabad-based biopharma startup Lamark Biotech has raised ₹6.5 crore in a pre-Series A funding round led by the IAN Group, including contributions from IAN Alpha Fund, BioAngels, and prominent angel investors such as Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel network played a central role in leading the investment.

Founded in 2018 by Vaibhav Bhatia, Lamark Biotech is pioneering drug delivery innovations for chronic and life-altering diseases through its proprietary ProteoStrong platform. This platform enables stabilization of fragile protein-based therapeutics, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure, addressing one of the biggest challenges in biologics storage and distribution.

The startup plans to use the fresh capital to accelerate development of its lead program, InsulinStrong, a thermostable insulin formulation designed to remain effective in extreme temperatures. Lamark’s product is particularly critical for regions with poor cold chain infrastructure, such as parts of India, Southeast Asia, and the Middle East.

In a statement, the company said the funds will also be deployed to expand its biologics pipeline, file international patents, commence early clinical trials, and forge partnerships with pharmaceutical companies, CDMOs, and global public health organizations.

Lamark Biotech previously raised $41,300 in a seed round led by VIT-TBI. The company operates from the Venture Center at NCL Innovation Park, a government-backed R&D hub for deep tech startups, and has garnered attention for tackling global health delivery challenges through temperature-resilient biologics.

The Indian insulin market, valued at ₹4,000 crore, represents a significant opportunity for Lamark, as it works toward improving drug accessibility and affordability in underserved geographies.

With thermostable insulin seen as a potential game-changer in diabetes care, Lamark Biotech’s breakthrough could help millions of patients access life-saving drugs without the need for continuous refrigeration — a step forward in democratizing healthcare delivery worldwide.

Follow Startup Story